Ticker brief
AMGN AMGEN INC
Consumer, Non-cyclical · Biotechnology
last close
$432.42
1 day
-1.0%
14 days
+4.1%
mkt cap
$201.9B
signals 14d
49
authors 14d
34
crowd 14d
+1.5σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 34% rich · 98 pctile own 1y | IV/HV 1.07× (as of 2026-07-31) |
| Skew — 25Δ RR 30d | -0.042 45 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +0.38 normal | 5-session Δ +0.07 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2025-01-10 (z=2.1) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-28 · now +0.20 (−1 bearish … +1 bullish)
Who spoke34
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | -0.45 | 4 | +0.06 |
| @KeithTradeSmith | C | +0.25 | 4 | +0.35 |
| @LaMonicaBuzz | B | +0.09 | 3 | +0.37 |
| @MartyChargin | C | -0.27 | 3 | +0.40 |
| @jom2jp | C | -1.83 | 2 | +0.23 |
| @AsafNaamani | C | -3.38 | 2 | +0.60 |
| @fwpharma | B | +0.98 | 2 | +0.20 |
| @CapitalFlowApp | C | · | 2 | +0.52 |
| @Amgen | C | · | 2 | +0.38 |
| @TalkMarkets | C | · | 1 | +0.35 |
| @PersimmonTI | A | -0.57 | 1 | -0.10 |
| @OracleNYSE | C | -0.08 | 1 | +0.00 |
| @StockPatternPro | C | -0.32 | 1 | +0.50 |
| @anandragn | C | -1.17 | 1 | +0.25 |
| @TheMarket_Monk | C | -1.30 | 1 | +0.15 |
| @PortfolioBoss | C | -1.86 | 1 | +0.50 |
| @shanaka86 | A | +1.96 | 1 | -0.50 |
| @Ben1148x2 | C | +1.01 | 1 | +0.40 |
| @UTEX_io | C | +0.61 | 1 | +0.40 |
| @AryaFintech | C | -1.31 | 1 | +0.30 |
| @schaeffers | C | +3.18 | 1 | +0.30 |
| @Trent_TACap | B | -0.04 | 1 | +0.70 |
| @ttvresearch | C | +0.30 | 1 | +0.00 |
| @SevenParr | C | -0.15 | 1 | +0.60 |
| @VladBastion | B | -1.80 | 1 | +0.35 |
Recent signals30of 49 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @Globalmess65 | +0.20 | Praises RVMD's launch and compares its rise with successful biotech precedents. | — | tweet ↗ |
| 2026-08-27 | @BiopharmIQ | +0.20 | Biotech mover list links price changes to company-specific catalysts. | -1.0% | tweet ↗ |
| 2026-08-27 | @OzmosiHealth | +0.50 | TEZSPIRE met both co-primary and all key secondary endpoints in Phase 3. | -1.0% | tweet ↗ |
| 2026-08-27 | @fwpharma | +0.40 | A pivotal Tezspire study win supports pursuit of a third indication in eosinophilic oesophagitis. | -1.0% | tweet ↗ |
| 2026-08-27 | @BioStocks | +0.50 | Reports positive Phase 3 TEZSPIRE results across both co-primary and all key secondary endpoints. | -1.0% | tweet ↗ |
| 2026-08-27 | @Amgen | +0.50 | Amgen directly announces positive top-line Phase 3 results in eosinophilic esophagitis. | -1.0% | tweet ↗ |
| 2026-08-26 | @adamfeuerstein | +0.20 | Frames NVS, AMGN and LLY as contenders in a multibillion-dollar Lp(a) drug-development race. | -1.8% | tweet ↗ |
| 2026-08-25 | @jom2jp | +0.25 | The tweet lists five U.S. stocks making new 52-week highs on August 25. | -2.2% | tweet ↗ |
| 2026-08-25 | @LaMonicaBuzz | +0.50 | Reports new record highs across copper, pharmaceutical and Canadian-bank stocks. | -2.2% | tweet ↗ |
| 2026-08-25 | @MartyChargin | +0.35 | Large-cap drug stocks are performing well, with LLY singled out as ready for a stronger move. | -2.2% | tweet ↗ |
| 2026-08-25 | @bioinvestor24 | -0.15 | Argues AMGN should consolidate oncology assets and identifies TNGX and ERAS as best fits. | -2.2% | tweet ↗ |
| 2026-08-25 | @Biotech2k1 | +0.15 | Notes two companies are commercial and three peers have late-stage or approval-pending products. | -2.2% | tweet ↗ |
| 2026-08-24 | @bioinvestor24 | +0.25 | Suggests expanded market caps give AMGN and ABBV capacity for stock-funded acquisitions. | -2.6% | tweet ↗ |
| 2026-08-24 | @cfaryanoconnell | +0.55 | Lists S&P 500 stocks making new all-time highs today. | -2.6% | tweet ↗ |
| 2026-08-24 | @TrendSpider | +0.65 | Lists S&P 500 constituents reaching new all-time highs; ticker output is capped at six. | -2.6% | tweet ↗ |
| 2026-08-24 | @KeithTradeSmith | +0.25 | Clarifies that Amgen challenges Lilly while Halo benefits as Lilly's delivery technology. | -2.6% | tweet ↗ |
| 2026-08-23 | @KeithTradeSmith | +0.00 | Says public filings and releases provide no evidence that Amgen uses Halozyme technology. | -1.6% | tweet ↗ |
| 2026-08-23 | @KeithTradeSmith | +0.50 | Frames simultaneous breakouts as a bullish market vote on the obesity-drug category. | -1.6% | tweet ↗ |
| 2026-08-23 | @MartyChargin | +0.40 | Enthusiastically frames four large drug companies as sector leaders. | -1.6% | tweet ↗ |
| 2026-08-23 | @KeithTradeSmith | +0.65 | Argues biotech is an underappreciated bull market supported by momentum, valuations and AI. | -1.6% | tweet ↗ |
| 2026-08-22 | @bioinvestor24 | +0.40 | Uses prior obesity-drug trial read-throughs to frame likely Phase 3 outcomes across a biotech basket. | -1.6% | tweet ↗ |
| 2026-08-21 | @LaMonicaBuzz | +0.25 | Ranks the five best year-to-date Dow performers with exact returns. | -1.6% | tweet ↗ |
| 2026-08-21 | @bioinvestor24 | -0.25 | Views VKTX data as rapidly interpretable and favors its 10 mg biweekly arm versus peers. | -1.6% | tweet ↗ |
| 2026-08-21 | @HunterAllen4 | +0.05 | Builds a long-horizon ONCY platform thesis from mechanistic, clinical and regulatory evidence. | -1.6% | tweet ↗ |
| 2026-08-21 | @VladBastion | +0.35 | Ranks healthcare momentum leaders and highlights renewed interest in beaten-down CRL. | -1.6% | tweet ↗ |
| 2026-08-21 | @Amgen | +0.25 | Amgen describes continued work to improve LDL-cholesterol management based on long-term evidence. | -1.6% | tweet ↗ |
| 2026-08-20 | @CapitalFlowApp | +0.65 | Reports a $21.4M AMGN 310-call sweep as bullish institutional positioning | -0.3% | tweet ↗ |
| 2026-08-20 | @CapitalFlowApp | +0.40 | Reports Argus raising AMGN's price target amid strong call flow | -0.3% | tweet ↗ |
| 2026-08-20 | @SevenParr | +0.60 | Cites large equity and options flows as confirmation of institutional investment and strength. | -0.3% | tweet ↗ |
| 2026-08-20 | @ttvresearch | +0.00 | Infographic ranks year-to-date performance of Dow components; individual values require the chart. | -0.3% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.